MRK•benzinga•
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Summary
Merck's Phase 3 trial shows subcutaneous pembrolizumab is as effective as IV Keytruda for first-line NSCLC treatment, meeting key pharmacokinetic goals.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga